US equities
|
MU
$1,066.38
▼-1.99%
NVDA
$236.04
▼-0.60%
PLTR
$201.16
▲+3.63%
SNDK
$1,645.70
▼-2.76%
META
$721.79
▲+0.07%
AMD
$635.90
▼-1.54%
TSLA
$372.26
▼-1.47%
INTC
$109.70
▼-3.02%
MU
$1,066.38
▼-1.99%
NVDA
$236.04
▼-0.60%
PLTR
$201.16
▲+3.63%
SNDK
$1,645.70
▼-2.76%
META
$721.79
▲+0.07%
AMD
$635.90
▼-1.54%
TSLA
$372.26
▼-1.47%
INTC
$109.70
▼-3.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Bausch + Lomb Corporation Common Shares
(NY:
BLCO
)
17.20
-0.14 (-0.81%)
Delayed Quote
Updated: 10:13 AM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bausch + Lomb Corporation Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Low-Volatility Stocks with Open Questions
Today 0:39 EDT
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...
Via
StockStory
3 Small-Cap Stocks That Concern Us
September 17, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
September 09, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
August 28, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance
↗
April 29, 2026
Via
Chartmill
3 Healthcare Stocks We Steer Clear Of
August 27, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
Via
StockStory
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
↗
August 25, 2026
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Via
Benzinga
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
August 24, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...
Via
StockStory
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
↗
August 24, 2026
Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at...
Via
MarketBeat
3 Stocks Under $50 We’re Skeptical Of
August 18, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
↗
August 13, 2026
Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.
Via
The Motley Fool
Topics
Regulatory Compliance
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength.
Via
The Motley Fool
Topics
Earnings
Bausch + Lomb Q2 Earnings Call Highlights
↗
July 29, 2026
Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook....
Via
MarketBeat
Topics
Earnings
Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
July 29, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil...
Via
StockStory
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
July 27, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Bausch + Lomb beat analysts’ ...
Via
StockStory
Topics
Artificial Intelligence
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead
July 22, 2026
Over the past six months, Bausch + Lomb’s stock price fell to $15.99. Shareholders have lost 7% of their capital, which is disappointing considering the S&P ...
Via
StockStory
Topics
Stocks
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
July 10, 2026
What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma t...
Via
StockStory
Topics
Artificial Intelligence
Economy
Initial Public Offering
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
July 06, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via
StockStory
3 Small-Cap Stocks We Steer Clear Of
June 30, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
1 Stock Under $50 to Own for Decades and 2 We Turn Down
June 25, 2026
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...
Via
StockStory
Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest
May 19, 2026
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...
Via
StockStory
3 Profitable Stocks We’re Skeptical Of
May 18, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript
↗
April 30, 2026
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript
Via
The Motley Fool
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
April 29, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q1 CY2026, with sales up 9.4% year on year to $1.24 billion. The company’...
Via
StockStory
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For
April 27, 2026
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before the bell. Here’s what to expect. Bausch + Lomb beat analysts’ reve...
Via
StockStory
Bausch Lomb BLCO Q2 2025 Earnings Transcript
↗
April 21, 2026
Bausch Lomb BLCO Q2 2025 Earnings Transcript
Via
The Motley Fool
Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript
↗
April 21, 2026
Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript
Via
The Motley Fool
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript
↗
April 21, 2026
Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript
Via
The Motley Fool
Topics
Initial Public Offering
3 Cash-Burning Stocks We Keep Off Our Radar
April 10, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...
Via
StockStory
Topics
Bankruptcy
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
April 08, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
Next >
